title: Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer.
abstract: OBJECTIVE
  Pharmacogenetic studies in breast cancer (BC) may predict the efficacy of tamoxifen and the toxicity of paclitaxel and capecitabine. We determined the frequency of polymorphisms in the CYP2D6 gene associated with activation of tamoxifen, and those of the genes CYP2C8, CYP3A5 and DPYD associated with toxicity of paclitaxel and capecitabine. We also included a IL-10 gene polymorphism associated with advanced tumor stage at diagnosis.
  
  
  METHODS
  Genomic DNAs from 241 BC patients from northeast Mexico were genotyped using DNA microarray technology.
  
  
  RESULTS
  For tamoxifen processing, CYP2D6 genotyping predicted that 90.8% of patients were normal metabolizers, 4.2% ultrarapid, 2.1% intermediate and 2.9% poor metabolizers. For paclitaxel and the CYP2C8 gene, 75.3% were normal, 23.4% intermediate and 1.3% poor metabolizers. Regarding the DPYD gene, only one patient was a poor metabolizer. For the IL-10 gene, 47.1% were poor metabolizers.
  
  
  CONCLUSIONS
  These results contribute valuable information towards personalizing BC chemotherapy in Mexican women.
authors.affiliation: Vitagenesis S.A. de C.V., Boulevard Puerta del Sol 1005, Colinas de San Jerónimo, Monterrey. N.L. C.P. 64630, Mexico.
authors.forename: Gregorio Antonio
authors.initials: GA
authors.lastname: Alcazar-González
authors.forename: Ana Laura
authors.initials: AL
authors.lastname: Calderón-Garcidueñas
authors.forename: María Lourdes
authors.initials: ML
authors.lastname: Garza-Rodríguez
authors.forename: Gabriela
authors.initials: G
authors.lastname: Rubio-Hernández
authors.forename: Sergio
authors.initials: S
authors.lastname: Escorza-Treviño
authors.forename: Estibaliz
authors.initials: E
authors.lastname: Olano-Martin
authors.forename: Ricardo Martín
authors.initials: RM
authors.lastname: Cerda-Flores
authors.forename: Ana Lilia
authors.initials: AL
authors.lastname: Castruita-Avila
authors.forename: Juan Francisco
authors.initials: JF
authors.lastname: González-Guerrero
authors.forename: Stéphane
authors.initials: S
authors.lastname: le Brun
authors.forename: Laureano
authors.initials: L
authors.lastname: Simon-Buela
authors.forename: Hugo Alberto
authors.initials: HA
authors.lastname: Barrera-Saldaña
mesh_terms: D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D000069287:Capecitabine; D065727:Cytochrome P-450 CYP2C8; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D051544:Cytochrome P-450 CYP3A / Q000235:genetics*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D005838:Genotype; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics*; D008800:Mexico; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use; D011110:Polymorphism, Genetic / Q000235:genetics*; D013030:Spain; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; C508609:IL10 protein, human; D013629:Tamoxifen; D003841:Deoxycytidine; D016753:Interleukin-10; D000069287:Capecitabine; D001189:Aryl Hydrocarbon Hydroxylases; C450259:CYP2C8 protein, human; C510164:CYP3A5 protein, human; D065727:Cytochrome P-450 CYP2C8; D019389:Cytochrome P-450 CYP2D6; D051544:Cytochrome P-450 CYP3A; D017239:Paclitaxel; D005472:Fluorouracil